Table 3– Sensitivity analysis: association (odds ratios) of metabolic syndrome and its components with incident asthma on medication
Metabolic componentsTotal nIncident asthma on medication#Model 1 OR (95% CI)Model 2+ OR (95% CI)Model 3§ OR (95% CI)
Waist circumference ≥88 cm in females, ≥102 cm in males2 5631191.80 (1.46–2.23)1.66 (1.34–2.06)1.55 (1.23–1.95)
Triglycerides ≥1.7 mmol·L−164011951.30 (1.08–1.57)1.21 (1.01–1.46)1.05 (0.86–1.29)
HDL cholesterol <1.3 mmol·L−1 in females, <1.0 mmol·L−1 in males41061501.39 (1.15–1.69)1.30 (1.07–1.58)1.18 (0.96–1.46)
Elevated blood pressureƒ or use of anti-hypertensive medication98592691.10 (0.92–1.31)1.07 (0.89–1.28)0.99 (0.82–1.19)
Elevated glucose## or diabetes501241.87 (1.23–2.85)1.76 (1.15–2.68)1.64 (1.07–2.52)
Metabolic syndrome¶¶ ≥3 components2413951.55 (1.23–1.94)1.42 (1.13–1.79)NA
  • Total n = 20 155. HDL: high-density lipoprotein; NA: not applicable. #: incident asthma definition requires use of an asthma medication at follow-up and excludes those with wheezing from at-risk group at baseline and follow-up. : adjusted for age, sex and family history of asthma. +: adjusted for age, sex, family history of asthma, smoking, physical activity, education, social benefit and economic difficulties at baseline. §: adjusted for all covariates and other metabolic risk factors. ƒ: systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg. ##: elevated glucose was ≥5.6 mmol·L−1 and ≥4 h since last meal. ¶¶: metabolic syndrome was defined according to the Joint Interim Statement clinical criteria including alternate indicators anti-hypertensive medication and diabetes; glucose was nonfasting and ≥4 h since last meal.